In vitro evaluation of Aurora kinase inhibitor—VX680—in formulation of PLA-TPGS nanoparticles

Tóm tắt

Polymeric nanoparticles prepared from poly(lactide)-tocopheryl polyethylene glycol succinate (PLA-TPGS) were used as potential drug carries with many advantages to overcome the disadvantages of insoluble anticancer drugs and enhance blood circulation time and tissues. VX680 is an Aurora kinase inhibitor and is also the foremost Aurora kinase inhibitor to be studied in clinical trials. In this study, we aimed to investigate whether VX680-loaded PLA-TPGS nanoparticles (VX680-NPs) are able to effectively increase the toxicity of chemotherapy. Accordingly, we first synthesized VX680-loaded nanoparticles and NP characterizations of morphology, mean size, zeta potential, and encapsulation efficiency were spherical shape, 63 nm, −30 mV and 76%, respectively. Then, we investigated the effects on HeLa cells. The cell cytotoxicity was evaluated by the xCELLigence real-time cell analyzer allowing measurement of changes in electrical impedance on the surface of the E-plate. Analysis of nucleus morphology and level of histone H3 phosphorylation was observed by confocal fluorescence scanning microscopy. Cell cycle distribution and apoptosis were analyzed by flow cytometry. Our results showed that VX680-NPs reduced cell viability with IC50 value lower 3.4 times compared to free VX680. Cell proliferation was inhibited by VX680-NPs accompanied by other effects such as high abnormal changes of nucleus, a decrease of phospho-histone H3 at Ser10 level, an increase of polyploid cells and resulted in higher apoptotic cells. These results demonstrated that VX680-NPs had more cytotoxicity than as treated with VX680 alone. Thus, VX680-NPs may be considered as promising drug delivery system for cancer treatment.

Từ khoá

Nanoparticle, VX680, PLA-TPGS, xCELLigence, Aurora kinase inhibitors

Tài liệu tham khảo

[1] Glover D M, Leibowitz M H, McLean D A and Parry H 1995 Cell 81 95
[2] Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya P S, Lepsik M and Hajduch M 2012 Invest. New Drug. 30 2411
[3] Zhang X-H et al 2008 Cancer Biol. Ther. 7 1388
[4] Zhang L and Zhang S 2011 J. Obstet. Gynaecol. Res. 37 591
[5] Lam A K-Y, Ong K and Ho Y-H 2008 Hum. Pathology 39 599
[6] Lee E C Y, Frolov A, Li R, Ayala G and Greenberg N M 2006 Cancer Res. 66 4996
[7] Terakawa T, Miyake H, Kumano M and Fujisawa M 2011 Oncol. Lett. 2 713
[8] Tanaka S et al 2008 Br. J. Surg. 95 611
[9] Kuang Y A N, Cai J, Li D, Han Q I N, Cao J I N and Wang Z 2013 Oncol. Lett. 5 1149
[10] Park H-S et al 2008 J. Nat. Cancer Inst. 100 1401
[11] Crosio C, Fimia G M, Loury R, Kimura M, Okano Y, Zhou H, Sen S, Allis C D and Sassone-Corsi P 2002 Mol. Cell. Biol. 22 874
[12] Seymour J F et al 2014 Blood Cancer J. 4 e238
[13] Tavanti E et al 2013 Br. J. Cancer 109 2607
[14] Fiskus W et al 2008 Clin. Cancer Res. 14 6106
[15] Harrington E A et al 2004 Nat. Med. 10 262
[16] Bertrand N, Wu J, Xu X, Kamaly N and Farokhzad O C 2014 Adv. Drug Deliv. Rev. 66 2
[17] Le D T T, Dang L T M, Hoang N T M, La H T and Nguyen H T M 2015 J. Nanomed. Nanotechnol. 6 267
[18] Madhavan Nampoothiri K, Nair N R and John R P 2010 Bioresource Technol. 101 8493
[19] Bergsma J E, de Bruijn W C, Rozema F R, Bos R R M and Boering G 1995 Biomaterials 16 25
[20] Tang X, Cai S, Zhang R, Liu P, Chen H, Zheng Y and Sun L 2013 Nanoscale Res. Lett. 8 420
[21] Zhang Z and Feng S-S 2006 Biomaterials 27 262
[22] Neophytou C M and Constantinou A I 2015 BioMed Res. Int. 2015 584862
[23] Thu H P, Nam N H, Quang B T, Son H A, Toan N L and Quang D T 2015 Saudi Pharm. J. 23 683
[24] Zhang Z, Mei L and Feng S-S 2012 Nanomedicine 7 1645
[25] Thu H P et al 2016 Adv. Nat. Sci.: Nanosci. Nanotechnol. 7 015001
[26] Thu H P et al 2013 Chem. Lett. 42 255
[27] Petros R A and DeSimone J M 2010 Nat. Rev. Drug Discovery 9 615
[28] Fang C, Shi B, Pei Y-Y, Hong M-H, Wu J and Chen H-Z 2006 Eur. J. Pharm. Sci. 27 27
[29] Dar A A, Goff L W, Majid S, Berlin J and El-Rifai W 2010 Mol. Cancer Ther. 9 268
[30] Hoang T M N, Favier B, Valette A, Barette C, Nguyen C H, Lafanechère L, Grierson D S, Dimitrov S and Molla A 2009 Cell Cycle 8 765
[31] Le L T T, Vu H L, Nguyen C H and Molla A 2013 Biol. Open 2 379
[32] Zhu Y, Zhou Y and Shi J 2014 Cell Cycle 13 1756
[33] Atienzar F A, Gerets H, Tilmant K, Toussaint G and Dhalluin S 2013 Biosensors 3 132
[34] Limame R, Wouters A, Pauwels B, Fransen E, Peeters M, Lardon F, De Wever O and Pauwels P 2012 PLoS One 7 e46536
[35] Pan T, Huang B, Zhang W, Gabos S, Huang D Y and Devendran V 2013 Anal. Chim. Acta 764 44
[36] Gizatullin F, Yao Y, Kung V, Harding M W, Loda M and Shapiro G I 2006 Cancer Res. 66 7668
[37] Kralj M, Husnjak K, Korbler T and Pavelic J 2003 Cancer Gene Ther. 10 457

Các bài trích dẫn đến

1. Cuu Khoa Nguyen, Ngoc Quyen Tran, Thi Phuong Nguyen, Dai Hai Nguyen. Biocompatible nanomaterials based on dendrimers, hydrogels and hydrogel nanocomposites for use in biomedicine in Advances in Natural Sciences: Nanoscience and Nanotechnology (Vol. 8, No. 1, 2017)
2. Kim Thach Nguyen, Thu Ha Nguyen, Dinh Ho Do, Quang Huan Le. Characterization of the paclitaxel loaded chitosan graft Pluronic F127 copolymer micelles conjugate with a DNA aptamer targeting HER-2 overexpressing breast cancer cells in Advances in Natural Sciences: Nanoscience and Nanotechnology (Vol. 8, No. 1, 2017)